---
title: "Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma"
description: "This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to ge"
url: "https://www.clareohealth.com/clinical-trials/NCT03743298"
---

This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of efficacy, in patients with measurable metastatic melanoma. The study is open to patients who have either never received treatment for metastatic melanoma or were previously treated with anti-PD-1 with or without anti-CTLA-4 or with enzymatic inhibitors of the BRAF/MEK pathway because of BRAF600E/K mutations, and are about to initiate anti-PD-1 monotherapy. The intent is to treat 14 to 20 patients with the combination of anti-PD-1 and AV-MEL-1.

## Key Facts

**ID:** NCT03743298
**Status:** UNKNOWN
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 20
**Sponsor:** Aivita Biomedical, Inc.

## About This Study

This clinical trial is testing AV-MEL-1, a treatment made from a patient's own immune cells mixed with their tumor's proteins, alongside standard anti-PD-1 therapy for metastatic melanoma. It is for adults with metastatic melanoma who are starting anti-PD-1 treatment and have a tumor that can be surgically removed.

## Conditions

- Metastatic Melanoma

## Interventions

**DRUG: AV-MEL-1**
AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.

## Eligibility

Inclusion Criteria: * Age \> 18 * Karnofsky Performance Status (KPS) of \> 70 * Presence of at least one metastatic lesion that is to be removed surgically as part of standard car…

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Jericho Rabago, Irvine, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

## Contact Information

**Jim Langford**
Email: jim@aivitabiomedical.com
Phone: 949-872-2555

## Important Dates

**Study start:** April 21, 2021

**Completion date:** May 1, 2026

**Last updated:** April 10, 2023

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have metastatic melanoma and are about to start anti-PD-1 therapy.
- You have a tumor that can be surgically removed as part of your treatment.
- You are interested in new treatment options that use your own immune cells.

### Questions to Ask

- What specific benefits might AV-MEL-1 provide alongside my anti-PD-1 treatment?
- How will my eligibility for this trial be determined?
- What are the potential side effects of AV-MEL-1 and the anti-PD-1 therapy?
- How often will I need to visit the clinic for treatment and monitoring?
- What happens if I experience side effects or if my condition changes during the trial?
- Can I continue my regular treatments while participating in this trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03743298)
